Literature DB >> 23939308

Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease.

Laura Parkkinen1, Sean S O'Sullivan, Catherine Collins, Aviva Petrie, Janice L Holton, Tamas Revesz, Andrew J Lees.   

Abstract

Progressive rostral spread of Lewy body (LB) pathology is thought to reflect the clinical course of Parkinson's disease (PD) although several studies have suggested that LBs are not the toxic species responsible for cell death. We investigated the relationship between nigral dopaminergic cell loss, distribution and density of α-synuclein-immunoreactive LBs and duration of motor symptoms in 97 patients with PD. Density of pigmented neurons was measured in a single section of one half of the substantia nigra (SN) with delineation of the dorsal and ventral tiers whereas the cortical and nigral LB densities were determined using a morphometric approach. The density of nigral neurons was estimated to decrease by 2% each year after confirmation of the clinical diagnosis of PD but showed marked heterogeneity with some PD patients with longer duration of illness still possessing a significant number of preserved pigmented nigral neurons at the time of death. An average 15% of surviving nigral neurones contained LBs and the age-adjusted proportion of LB-bearing neurons appeared relatively stable throughout the disease duration. No difference was observed in the age at death or duration of disease with respect to Braak PD stages. The nigral neuronal density was unrelated to either the Braak PD stage or to cortical LB densities. We conclude that nigral neuronal loss is slow and shows considerable variation in PD. Our data also provides no support for a primary pathogenic role of LBs as neither their distribution nor density was associated with the severity of nigral cell loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23939308      PMCID: PMC4196643          DOI: 10.3233/JPD-2011-11046

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  43 in total

Review 1.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Authors:  Byron Caughey; Peter T Lansbury
Journal:  Annu Rev Neurosci       Date:  2003-04-09       Impact factor: 12.449

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 3.  Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease.

Authors:  G M Halliday; K Del Tredici; H Braak
Journal:  J Neural Transm Suppl       Date:  2006

4.  Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.

Authors:  M Lee; D Hyun; B Halliwell; P Jenner
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

5.  Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia.

Authors:  Laura Parkkinen; Tarja Kauppinen; Tuula Pirttilä; Jaana M Autere; Irina Alafuzoff
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

6.  Cognitive status correlates with neuropathologic stage in Parkinson disease.

Authors:  H Braak; U Rüb; E N H Jansen Steur; K Del Tredici; R A I de Vos
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

7.  Ageing and Parkinson's disease: substantia nigra regional selectivity.

Authors:  J M Fearnley; A J Lees
Journal:  Brain       Date:  1991-10       Impact factor: 13.501

Review 8.  Research in motion: the enigma of Parkinson's disease pathology spread.

Authors:  Patrik Brundin; Jia-Yi Li; Janice L Holton; Olle Lindvall; Tamas Revesz
Journal:  Nat Rev Neurosci       Date:  2008-09-04       Impact factor: 34.870

9.  Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Authors:  Yaroslau Compta; Laura Parkkinen; Sean S O'Sullivan; Jana Vandrovcova; Janice L Holton; Catherine Collins; Tammaryn Lashley; Constantinos Kallis; David R Williams; Rohan de Silva; Andrew J Lees; Tamas Revesz
Journal:  Brain       Date:  2011-05       Impact factor: 13.501

10.  Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance.

Authors:  Laura Parkkinen; Tuula Pirttilä; Irina Alafuzoff
Journal:  Acta Neuropathol       Date:  2008-02-23       Impact factor: 17.088

View more
  30 in total

1.  Alpha-synuclein: prion or prion-like?

Authors:  Rehana K Leak; Matthew P Frosch; Thomas G Beach; Glenda M Halliday
Journal:  Acta Neuropathol       Date:  2019-08-12       Impact factor: 17.088

2.  Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models.

Authors:  Xiaomin Su; D Luke Fischer; Xin Li; Krystof Bankiewicz; Caryl E Sortwell; Howard J Federoff
Journal:  Mol Ther       Date:  2017-05-15       Impact factor: 11.454

3.  Neural reserve, neuronal density in the locus ceruleus, and cognitive decline.

Authors:  Robert S Wilson; Sukriti Nag; Patricia A Boyle; Loren P Hizel; Lei Yu; Aron S Buchman; Julie A Schneider; David A Bennett
Journal:  Neurology       Date:  2013-03-13       Impact factor: 9.910

Review 4.  Is Braak staging valid for all types of Parkinson's disease?

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2018-06-25       Impact factor: 3.575

Review 5.  Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.

Authors:  David J Irwin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2013-07-31       Impact factor: 34.870

Review 6.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

7.  Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.

Authors:  Mechelle M Lewis; Guangwei Du; Jennifer Baccon; Amanda M Snyder; Ben Murie; Felicia Cooper; Christy Stetter; Lan Kong; Christopher Sica; Richard B Mailman; James R Connor; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

Review 8.  Parkinson's Disease Is Not Simply a Prion Disorder.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  J Neurosci       Date:  2017-10-11       Impact factor: 6.167

9.  100 years of Lewy pathology.

Authors:  Michel Goedert; Maria Grazia Spillantini; Kelly Del Tredici; Heiko Braak
Journal:  Nat Rev Neurol       Date:  2012-11-27       Impact factor: 42.937

Review 10.  Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?

Authors:  Alberto J Espay; Lorraine V Kalia; Ziv Gan-Or; Caroline H Williams-Gray; Philippe L Bedard; Steven M Rowe; Francesca Morgante; Alfonso Fasano; Benjamin Stecher; Marcelo A Kauffman; Matthew J Farrer; Chris S Coffey; Michael A Schwarzschild; Todd Sherer; Ronald B Postuma; Antonio P Strafella; Andrew B Singleton; Roger A Barker; Karl Kieburtz; C Warren Olanow; Andres Lozano; Jeffrey H Kordower; Jesse M Cedarbaum; Patrik Brundin; David G Standaert; Anthony E Lang
Journal:  Neurology       Date:  2020-02-26       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.